Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ)

CNY 18.05

(-0.55%)

Market Cap (In CNY)

20.12 Billion

Revenue (In CNY)

3.47 Billion

Net Income (In CNY)

861.3 Million

Avg. Volume

8.71 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
12.93-27.7
PE
-
EPS
-
Beta Value
0.898
ISIN
CNE100002Q33
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ms. Hui Zhou
Employee Count
-
Website
https://www.biokangtai.com
Ipo Date
2017-02-08
Details
Shenzhen Kangtai Biological Products Co., Ltd. researches, develops, produces, and sells various types of human vaccines in China. The company's products include cell-free whitebait b-type haemophilus influenzae combined vaccine, SARS-COV-2 vaccine, recombinant hepatitis B vaccine, 23-valent pneumococcal polysaccharide vaccine, diphtheria tetanus acellular pertussis and haemophilus influenzae type b combined vaccine, haemophilus influenzae type b conjugate vaccine, measles and rubella combined with live attenuated vaccine, 13-valent pneumococcal conjugate vaccine, rabies vaccine, inactivated poliomyelitis vaccine, and HIB conjugate vaccine. It has an agreement between YTB and Yong Tai Berhad in relation to the development and commercialization of Covid-19 inactivated vaccine in Malaysia. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is based in Shenzhen, China.